Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGRX-814 in hematological malignancies
NCT06206174Phase 2Recruiting
- Sponsor
- Shenzhen TargetRx
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TGRX-814 in non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), sponsored by Shenzhen TargetRx. Started Mar 2024; status: recruiting.
02
Drugs
TGRX-814
03
Conditions
non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06206174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206174.